Merck Serono, a division of Merck KGaA, has modified the license from Oncothyreon to include the right to manufacture Stimuvax (BLP25 liposome vaccine) and also has purchased current inventory and certain assets used for the manufacture of Stimuvax from Oncothyreon Inc for a total amount of approximately US$13 million.
The details can be read here.
No comments:
Post a Comment